White House Health Advisor Anthony Fauci said Monday that protection from any potential coronavirus vaccine may be short-lived and that a booster is needed to increase safety.
As most companies move closer to the finish line of a potential vaccine for the virus, the role of antibodies is even more important because it can determine how well a vaccine works and how often someone receives it. May be required, or booster, long-term care.
Responding to a question about how long antibodies protect against infection, Fouci said Monday that "we don't know."
"With this spike protein as we do it with primes and in some cases growing up, we think there is some degree of protection, but we want to think that it is limited," said Dr. National, director of the National Institutes of Health. Included in a questionnaire discussion with Francis Collins. "It's not like Meijles vaccine."
According to the Centers for Disease Control and Prevention, measles, almonds and rubella vaccine usually provide lifelong immunity. Any potential coronavirus vaccine is unlikely to do so, Fauci said.
"So we have a case to follow in those cases to see if we need osteopathy," he said. "We may need osteo to continue conservation, but we don't know how long it will be right now."
Fouci, director of the National Institute of Allergy and Infectious Diseases, said reports of Kovid-19 patients getting infected are untrue. He said the test was more likely to be used to detect Kovid-19, which may have been through the removal of virus fragments in the recovering patient's body, but that they had not been tested again.
“There are no cases where people have recovered and become infected again with viruses,” he said. "I would not be surprised if there was a rare case of a man who went into remission.
They reported that some of the viruses, including Ebola, showed the ability to infect the recovered patients.
Fauci has previously stated that the coronavirus vaccine may not provide long-term immunity.
"When you look at the history of coronavirus - the common coronavirus that causes the common cold - there have been reports in the literature that immunity lasts for three to six months and is almost always less than a year," he said last month. "It's not very durable and protective."
Before vaccinations were proven to be safe and effective in humans, any protection would be welcomed in vulnerable groups, such as health workers and the elderly, prioritized by the Emergency Use Authority.
Officials will now find out if the vaccine candidate for development is safe and effective by 2021, Fauci said Monday, sticking with authorities from the time before March. British cement company AstraZeneca and the US Biotech company Modern are the two companies to develop their vaccine candidates.
Corona has accelerated its potential vaccine development with the National Institutes of Health Modern as part of "Operation War Speed," a federal effort to accelerate the development of the virus vaccine.
Although the company's shares were down last week when STAT News reported that the company was delaying the start date of the trial, Moderno hopes to transfer its candidate for three trials before the end of this month. The third stage test is the most comprehensive test the candidate will face, with about 30,000 test participants. If all goes well and the candidate proves to be safe and effective in humans, the vaccine can be delivered before the end of the year.
The World Health Organization said last week that there are 16 companies with vaccines in human trials worldwide. More than 10 companies in the US are already undergoing human testing or are due to launch soon.
“We hope to have at least one answer to whether vaccines or vaccines are plural, safe and effective by the end of this year or early 2021,” Fauci said.
0 Comments